Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer

  • Clarke N
  • 19


    Mendeley users who have this article in their library.
  • 4


    Citations of this article.


• The treatment of metastatic and castration-resistant prostate cancer (CRPC) has advanced considerably from the era where it was considered that the disease was resistant to chemotherapy. • Cytotoxic chemotherapy involving docetaxel is now used routinely as a first-line therapy after failed first- and second-line androgen deprivation in advanced disease, improving quality of life and to a limited extent, survival in patients with advanced prostate cancer. • The cytotoxic taxane, cabazitaxel has also become a second-line treatment option for patients with CRPC failing previous docetaxel therapy. • Additionally, a broad range of agents are now available or under development including immune-based therapies (cellular therapies and vaccines), bone-targeting agents (anti-osteolytic and anti-tumour therapies) and molecular-based agents targeting cellular control mechanisms. • Most of these remain experimental but on-going pharmacological development will inevitably provide urologists and urological oncologists with a broader range of therapeutic options for better cancer management in the future.

Author-supplied keywords

  • castration-resistant prostate cancer
  • chemotherapy
  • immunotherapy
  • prostate cancer
  • survival
  • treatment

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Noel W. Clarke

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free